Daratumumab: A new future for AL-Amyloidosis and Multiple Myeloma
Concomitant development of symptomatic amyloid light-chain (AL) amyloidosis and multiple myeloma (MM) is rare and has a poor survival rate. Introduction of thalidomide and bortezomib, a proteasome inhibitor, has improved the survival of patients with MM; however, it has not cured the disease. Nevert...
| Autor principal: | |
|---|---|
| Outros Autores: | , , , |
| Formato: | report |
| Idioma: | eng |
| Publicado em: |
2020
|
| Assuntos: | |
| Texto completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S0872-01692020000300008 |
| País: | Portugal |
| Oai: | oai:scielo:S0872-01692020000300008 |